For pancreatic adenocarcinoma, EGFR expression levels reported in different series have ranged from 25% to 90%, and EGFR expression has been shown to be associated with advanced stage, metastatic disease, and poor differentiation and survival [6,7,13,15,16,17]. This evidence concerns the gene EGFR and pancreatic adenocarcinoma.